北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 临床药理研究所  > 期刊论文
学科主题: 药理学
题名:
β内酰胺类/β内酰胺酶抑制剂的体外抗菌活性研究
其他题名: Antibacterial activity study of several β-lactam/β-lactamase inhibitor combinations in vitro
作者: 欧尾妹; 吕媛; 李耘; 薛峰; 刘健; 杨维维; 张佳
关键词: β内酰胺类/β内酰胺酶抑制剂 ; 最低抑菌浓度 ; 细菌耐药 ; 超广谱β内酰胺酶 ; β-lactam/β-lactam inhibitor combinations ; minimum inhibitory concentration ; resistance ; extended-spectrumβ-lactamase
刊名: 中国临床药理学杂志
发表日期: 2015
DOI: 10.13699/j.cnki.1001-6821.2015.11.006
期: 11, 页:916-920
收录类别: 中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型: Journal Article
摘要: 目的:比较不同β内酰胺类/β内酰胺酶抑制剂对肠杆菌科细菌的体外抗菌活性。方法收集临床分离肠杆菌科细菌,用平皿二倍稀释法测定抗菌药最低抑菌浓度( MIC),根据2014版美国临床实验室标准化委员会( CLSI)折点判读结果,用SPSS17.0统计软件处理数据。结果共收集到2166株肠杆菌科细菌。哌拉西林对大肠埃希菌的MIC50和MIC90分别是256,512μg· mL-1,加用他唑巴坦后MIC50和MIC90则分别为2,8μg· mL-1。对产超广谱β内酰胺酶( ESBLs)大肠埃希菌和肺炎克雷伯菌,哌拉西林/他唑巴坦敏感率最高为93.7%和86.1%,头孢哌酮/他唑巴坦为91.59%和82.59%,头孢哌酮/舒巴坦为74.4%和58.37%。复方制剂对非产ESBLs大肠埃希菌和肺炎克雷伯菌的敏感率与单用β内酰胺类相差不大。β内酰胺类抗菌药对普通变形杆菌的敏感率比奇异变形杆菌高,但加用β内酰胺酶抑制剂后两者敏感率差不多。美洛西林/舒巴坦对摩根菌属敏感率为97.4%,明显高于单用美洛西林的76.3%。头孢噻肟/他唑巴坦和头孢曲松/他唑巴坦对肠杆菌科细菌的MIC90比单用头孢噻肟和头孢曲松低。结论β内酰胺类/β内酰胺酶抑制剂对肠杆菌科细菌的抗菌活性比单用β内酰胺类抗菌药强,尤其对产ESBLs大肠埃希菌和肺炎克雷伯菌差异更为明显,其中以哌拉西林/他唑巴坦的抗菌活性最强。 Objective To evaluate the antibacterial activities of severalβ-lactam/β-lactam inhibitor combinations in vitro.Methods All the clinical isolates were Enterobacteriaceae collected from hospitals and the susceptibility tests were performed using agar dilution method recom-mended by CLSI.The minimum inhibitory concentration ( MIC ) results were interpreted according to the breakpoints of CLSI (2014) guideline.The data was analyzed by software SPSS17.0.Results A total of 2166 Enterobacteriaceae were collected and were performed MIC tests.Based on the MIC results, the MIC50 and MIC90 of piperacillin to Escherichia coli were 256 , 512 μg · mL-1 , while piperacillin/tazobactam were 2 , 8μg· mL-1 , respectively.The sensitive rates of piperacillin/tazobactam to ESBLs -producing Escherichia coli and Klebsiella pneumoniae were 93.7% and 86.1%, cefoperazone/tazobactam were 91.5% and 82.5%, while cefoperazone /sulbactam were 74.4% and 58.39%. Among ESBLs -non -producing Escherichia coli and Klebsiella pneumoniae, there is not much difference between using β-lactam/β-lactam inhibitor combinations and β-lactams alone.β-lactam antibiotics have higher sensitive rates to Proteus vulgaris than Proteus mirabilis, butβ-lactam/β-lactam inhibitor combinations have no difference against them.The sensitive rate of mezlocillin/sulbactam to Morganella spp.was 97.4%, significantly higher than mezlocillin alone with sensitive rate 76.3%.The MIC90 of cefotaxime/tazobactam and ceftriaxone/tazobactam were lower than using cefotaxime and ceftriaxone alone.Conclusion β-lactam/β-lactam inhibitor combinations have greater antimicrobial activity to Enterobacteriaceae than β-lactams alone, especially for ESBLs-producing Escherichia coli and Klebsiella pneumoniae.Among them, piperacillin/tazobactam has the greatest antimicrobial activity.
语种: 中文
原文出处: 查看原文
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/44478
Appears in Collections:北京大学第一临床医学院_临床药理研究所_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 北京大学第一医院 临床药理研究所,北京,100191

Recommended Citation:
欧尾妹,吕媛,李耘,等. β内酰胺类/β内酰胺酶抑制剂的体外抗菌活性研究[J]. 中国临床药理学杂志,2015(11):916-920.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[欧尾妹]'s Articles
[吕媛]'s Articles
[李耘]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[欧尾妹]‘s Articles
[吕媛]‘s Articles
[李耘]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace